Ibrutinib in CLL: benefit for all?
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.
This segment covers the diagnosis and initial treatment of a case of severe, multi-organ cGvHD, including the use of high-dose corticosteroids and other systemic agents.
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival…
Data support using 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.
Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
Ascites are abnormal pockets of fluid that develop in the abdomen. We spoke to gynecologic oncologist Travis Sims, M.D., to learn more about this late-stage…